Colorectal CancerCOSA-RCTNCT07242820
Reducing Neoplasia Recurrence After Non-thermal Endoscopic Resection of Large Colorectal Polyps
A study testing Adjuvant thermal ablation and No adjuvant thermal ablation in people with Colorectal Cancer and Polyp of Colon, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.
Trial summary
The goal of this clinical trial is to clarify the role of adjuvant thermal ablation for non-thermal endoscopic mucosal resection (EMR) of large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions [LSLs]). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Colorectal Cancer, Polyp of Colon
- What is being tested?
- Adjuvant thermal ablation and No adjuvant thermal ablation
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 752 participants
- Where
- 1 siteCanada
- Study dates
- Dec 2026to May 2032
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult patients
- Undergoing EMR for large (≥20 mm) colorectal LSL
- Providing written and informed consent for study participation
Who cannot join
- Inflammatory bowel disease
- Non-elective colonoscopy
- Poor general health (American Society of Anesthesiologists classification >III)
- Coagulopathy or thrombocytopenia (international normalized ration ≥1.5 or platelets <50*10^9/L)
- Bulky lesions (granular mixed with ≥10mm module).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec
Samira Hanin, 514-890-8000 ext. 30916, samira.hanin.chum@ssss.gouv.qc.ca
Daniel von Renteln, MD
About this study
The goal of this clinical trial is to clarify the role of adjuvant thermal ablation for non-thermal endoscopic mucosal resection (EMR) of large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions [LSLs]).
The hypothesis is that adding adjuvant thermal ablation to non-thermal EMR (vs no ablation) will result in lower lesion recurrence rates at 6-month follow-up, and non-inferior adverse events (AE) rates 14 days post EMR.
Read more
For participants with planned EMR, endoscopists will perform non-thermal EMRs as per standard of care and:
- adjuvant thermal ablation will either not be performed (control group), or will be applied to the base and outside margins of the resection site (experimental group);
- then, all patients will be contacted 14-44 days after EMR, to verbally ascertain the occurrence of AEs;
- then, all patients will undergo a first follow-up colonoscopy at 6 months after initial conoloscopy to assess lesion recurrence;
- finally, all patients will undergo a second and final colonoscopy 18 months after EMR.
Read the detailed description
This trial is an open-label, two-arm, parallel-group, multicenter RCT with co-primary outcomes (superiority for recurrence, non-inferiority for AEs). Patients undergoing non-thermal EMR will be randomized (1:1) to adjuvant thermal ablation (experimental group) or no ablation (control group).
All participating endoscopists will view dedicated teaching videos of the standard thermal ablation technique and key technical details to ensure consistent study procedures. Patients with planned EMR procedures will be invited by a research assistant before the EMR to participate in the study. Patients will be randomized to control or experimental groups in a 1:1 ratio using a central REDCap randomization module after the EMR resection phase is completed and immediately before adjuvant thermal ablation (intervention). This will limit bias by ensuring that the EMR technique is not affected by group allocation. When 2 or more lesions are present in a patient, the largest lesion will be chosen for inclusion in the study and all lesions will be photodocumented for auditing purposes.
No ablation (control group): Non-thermal EMR will be performed as per standard of care with submucosal injection and non-electrocautery resection of all visually visible polyp tissue using a snare. When the endoscopist determines that the resection is complete, no adjuvant thermal ablation of the post-EMR defect will be performed. Defect closure using clips will be performed only if there is concern for injury to the muscle layer or signs of overt perforation. A tattoo will be placed 3 cm distal to the resected lesion to allow for better identification of the resection site for follow-up. If multiple large polyps are found and removed, the largest lesion (study polyp) will be marked with two tattoos 3 cm distally and 3 cm proximally, to clearly identify the study polyp resection site.
Adjuvant thermal ablation (experimental group): Non-thermal EMR will be performed as per standard of care with submucosal injection and non-electrocautery resection of all visually visible polyp tissue using a snare. When the endoscopist determines that the resection is complete, submucosal injection (0.9% NaCl with methylene blue solution) using the h-APC probe (ERBEJET 2 attached to Vio3 electrosurgical unit, pressure: 40 bar) will be performed to further expose the resection margin. Adjuvant thermal ablation will be applied to the outside margins of the resection site using the h-APC probe. Then, adjuvant thermal ablation will also be applied to the base of the resection site using the h-APC probe. The precise electrocautery mode (PRECISE-APC setting 9) will be used to apply thermal ablation, as previously described for h-APC. Defect closure using clips will be performed only if there is concern for injury to the muscle layer or signs of overt perforation. A tattoo will be placed in the same way as described in the control group and, again, if multiple large polyps are found and removed, the largest lesion (study polyp) will be marked with two tattoos 3 cm distally and 3 cm proximally, to clearly identify the study polyp resection site.
At 6 months after initial colonoscopy, patients will undergo a first follow-up colonoscopy, as suggested by current guidelines and from studies showing that most recurrences occurred within the first 6 months. A window of 3 to 13 months will be permitted for the first follow-up. If recurrence is detected, patients will undergo subsequent colonoscopies at shortened intervals, as determined by the treating endoscopist, until no recurrence is detected. If surgery is performed due to difficulty in treating recurrence, patients will undergo a follow-up colonoscopy 6 months after surgery to detect any possible recurrence. All patients will undergo a second and final study colonoscopy 18 months after randomization, which will also mark the end of study follow-up. The second follow-up may be conducted within a window of 14 to 24 months. Subsequent colonoscopies will then be recommended outside the study as per routine care for such a clinical situation.
- Conditions
- Colorectal Cancer, Polyp of Colon
- Being tested
- Adjuvant thermal ablation, No adjuvant thermal ablation
- Medical subject headings
- Colorectal Neoplasms, Colonic Polyps
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Adjuvant thermal ablationProcedure or surgery
When the endoscopist determines that the resection is complete, submucosal injection (0.9% NaCl with methylene blue solution) using the h-APC probe (ERBEJET 2 attached to Vio3 electrosurgical unit, pressure: 40 bar) will be performed to further expose the resection margin. Adjuvant thermal ablation will be applied to the outside margins of the resection site using the h-APC probe.
Adjuvant thermal ablation will then also be applied to the base of the resection site using the h-APC probe. The precise electrocautery mode (PRECISE-APC setting 9) will be used to apply thermal ablation, as previously described for h-APC.
No adjuvant thermal ablationProcedure or surgery
After performing non-thermal EMR with thermal ablation, adjuvant thermal ablation will not be performed.
| Study group | Role | What they receive |
|---|---|---|
| Endoscopic mucosal resection (EMR) + adjuvant thermal ablation | Experimental | Adjuvant thermal ablation will be applied to the base and outside margins of the resection site after non-thermal EMR. Receives: Procedure: Adjuvant thermal ablation |
| Endoscopic mucosal resection (EMR) | Active comparator | After non-thermal EMR, no adjuvant thermal ablation will be performed. Receives: Procedure: No adjuvant thermal ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Lesion recurrence rate
Defined as the number of cases with pathology-confirmed hyperplastic, serrated, or adenomatous histology at the tattooed resection site compatible with the study polyp histology divided by the total number of cases.
Measured: 6 months
Clinically significant adverse event (AE) rate
Defined as the number of cases with delayed bleeding (blood per rectum resulting in emergency room visit, unplanned hospitalization, endoscopic, radiologic, or surgical intervention) and/or delayed perforation (endoscopic or radiologic evidence of significant air or any luminal contents outside the gastrointestinal tract) divided by the total number of cases.
Measured: 14 days
Secondary outcomes (2)
Any delayed bleeding rate
Defined as the number of cases with blood per rectum, regardless of clinical significance, divided by the total number of cases.
Measured: 14 days
Lesion recurrence rate at 18-month follow-up
Defined as the number of cases with pathology-confirmed hyperplastic, serrated, or adenomatous histology at the tattooed resection site compatible with the study polyp histology divided by the total number of cases.
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study startDec 2026 (estimated)
- Primary completionMay 2031 (estimated)
- Study completionMay 2032 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- More trials run by Centre hospitalier de l'Université de Montréal (CHUM)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 752 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07242820
- Sponsor's protocol ID
- 2026-13165
- Acronym
- COSA-RCT
- Status last verified
- Nov 2025
- First submitted
- 17 Nov 2025
- Last updated
- 14 Aug 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices).
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Reducing Neoplasia Recurrence After Non-thermal Endoscopic Resection of Large Colorectal Polyps
- ClinicalTrials.gov ID
- NCT07242820
- Acronym / sponsor ID
- COSA-RCT / 2026-13165
- Conditions
- Colorectal Cancer, Polyp of Colon
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 752 participants (estimated)
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)University, hospital or other
- Study start
- Dec 2026 (estimated)
- Primary completion
- May 2031 (estimated)
- Study completion
- May 2032 (estimated)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to clarify the role of adjuvant thermal ablation for non-thermal endoscopic mucosal resection (EMR) of large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions [LSLs]).
The hypothesis is that adding adjuvant thermal ablation to non-thermal EMR (vs no ablation) will result in lower lesion recurrence rates at 6-month follow-up, and non-inferior adverse events (AE) rates 14 days post EMR.
For participants with planned EMR, endoscopists will perform non-thermal EMRs as per standard of care and:
- adjuvant thermal ablation will either not be performed (control group), or will be applied to the base and outside margins of the resection site (experimental group);
- then, all patients will be contacted 14-44 days after EMR, to verbally ascertain the occurrence of AEs;
- then, all patients will undergo a first follow-up colonoscopy at 6 months after initial conoloscopy to assess lesion recurrence;
- finally, all patients will undergo a second and final colonoscopy 18 months after EMR.
Detailed description
This trial is an open-label, two-arm, parallel-group, multicenter RCT with co-primary outcomes (superiority for recurrence, non-inferiority for AEs). Patients undergoing non-thermal EMR will be randomized (1:1) to adjuvant thermal ablation (experimental group) or no ablation (control group).
All participating endoscopists will view dedicated teaching videos of the standard thermal ablation technique and key technical details to ensure consistent study procedures. Patients with planned EMR procedures will be invited by a research assistant before the EMR to participate in the study. Patients will be randomized to control or experimental groups in a 1:1 ratio using a central REDCap randomization module after the EMR resection phase is completed and immediately before adjuvant thermal ablation (intervention). This will limit bias by ensuring that the EMR technique is not affected by group allocation. When 2 or more lesions are present in a patient, the largest lesion will be chosen for inclusion in the study and all lesions will be photodocumented for auditing purposes.
No ablation (control group): Non-thermal EMR will be performed as per standard of care with submucosal injection and non-electrocautery resection of all visually visible polyp tissue using a snare. When the endoscopist determines that the resection is complete, no adjuvant thermal ablation of the post-EMR defect will be performed. Defect closure using clips will be performed only if there is concern for injury to the muscle layer or signs of overt perforation. A tattoo will be placed 3 cm distal to the resected lesion to allow for better identification of the resection site for follow-up. If multiple large polyps are found and removed, the largest lesion (study polyp) will be marked with two tattoos 3 cm distally and 3 cm proximally, to clearly identify the study polyp resection site.
Adjuvant thermal ablation (experimental group): Non-thermal EMR will be performed as per standard of care with submucosal injection and non-electrocautery resection of all visually visible polyp tissue using a snare. When the endoscopist determines that the resection is complete, submucosal injection (0.9% NaCl with methylene blue solution) using the h-APC probe (ERBEJET 2 attached to Vio3 electrosurgical unit, pressure: 40 bar) will be performed to further expose the resection margin. Adjuvant thermal ablation will be applied to the outside margins of the resection site using the h-APC probe. Then, adjuvant thermal ablation will also be applied to the base of the resection site using the h-APC probe. The precise electrocautery mode (PRECISE-APC setting 9) will be used to apply thermal ablation, as previously described for h-APC. Defect closure using clips will be performed only if there is concern for injury to the muscle layer or signs of overt perforation. A tattoo will be placed in the same way as described in the control group and, again, if multiple large polyps are found and removed, the largest lesion (study polyp) will be marked with two tattoos 3 cm distally and 3 cm proximally, to clearly identify the study polyp resection site.
At 6 months after initial colonoscopy, patients will undergo a first follow-up colonoscopy, as suggested by current guidelines and from studies showing that most recurrences occurred within the first 6 months. A window of 3 to 13 months will be permitted for the first follow-up. If recurrence is detected, patients will undergo subsequent colonoscopies at shortened intervals, as determined by the treating endoscopist, until no recurrence is detected. If surgery is performed due to difficulty in treating recurrence, patients will undergo a follow-up colonoscopy 6 months after surgery to detect any possible recurrence. All patients will undergo a second and final study colonoscopy 18 months after randomization, which will also mark the end of study follow-up. The second follow-up may be conducted within a window of 14 to 24 months. Subsequent colonoscopies will then be recommended outside the study as per routine care for such a clinical situation.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Endoscopic mucosal resection (EMR) + adjuvant thermal ablation | Experimental | Procedure: Adjuvant thermal ablationAdjuvant thermal ablation will be applied to the base and outside margins of the resection site after non-thermal EMR. |
| Endoscopic mucosal resection (EMR) | Active comparator | Procedure: No adjuvant thermal ablationAfter non-thermal EMR, no adjuvant thermal ablation will be performed. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Adult patients
- Undergoing EMR for large (≥20 mm) colorectal LSL
- Providing written and informed consent for study participation
Key exclusion criteria (5 listed)
- Inflammatory bowel disease
- Non-elective colonoscopy
- Poor general health (American Society of Anesthesiologists classification >III)
- Coagulopathy or thrombocytopenia (international normalized ration ≥1.5 or platelets <50*10^9/L)
- Bulky lesions (granular mixed with ≥10mm module).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Adjuvant thermal ablationWhen the endoscopist determines that the resection is complete, submucosal injection (0.9% NaCl with methylene blue solution) using the h-APC probe (ERBEJET 2 attached to Vio3 electrosurgical unit, pressure: 40 bar) will be performed to further expose the resection margin. Adjuvant thermal ablation will be applied to the outside margins of the resection site using the h-APC probe. Adjuvant thermal ablation will then also be applied to the base of the resection site using the h-APC probe. The precise electrocautery mode (PRECISE-APC setting 9) will be used to apply thermal ablation, as previously described for h-APC. | Procedure or surgery | Endoscopic mucosal resection (EMR) + adjuvant thermal ablation |
| No adjuvant thermal ablationAfter performing non-thermal EMR with thermal ablation, adjuvant thermal ablation will not be performed. | Procedure or surgery | Endoscopic mucosal resection (EMR) |
Primary outcome
Lesion recurrence rate
Time frame: 6 months
Defined as the number of cases with pathology-confirmed hyperplastic, serrated, or adenomatous histology at the tattooed resection site compatible with the study polyp histology divided by the total number of cases.
Clinically significant adverse event (AE) rate
Time frame: 14 days
Defined as the number of cases with delayed bleeding (blood per rectum resulting in emergency room visit, unplanned hospitalization, endoscopic, radiologic, or surgical intervention) and/or delayed perforation (endoscopic or radiologic evidence of significant air or any luminal contents outside the gastrointestinal tract) divided by the total number of cases.
2 secondary outcomes
Any delayed bleeding rate
Time frame: 14 days
Lesion recurrence rate at 18-month follow-up
Time frame: 18 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2026.
- Individual participant dataSharing planned: Yes. Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures and appendices).
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Centre Hospitalier de l'Université de Montréal
Montreal, Canada
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Adjuvant thermal ablation and No adjuvant thermal ablation in people with Colorectal Cancer and Polyp of Colon, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 14 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Lesion recurrence rate (time frame: 6 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2026.